AR-13503

CAT:
804-HY-12798C-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
AR-13503 - image 1

AR-13503

  • Description:

    AR-13503 (AR-13324 M1 metabolite) is the hydrolytic metabolite of AR-13324 mesylate. AR-13324 is a ROCK kinase and PKC inhibitor with anti-angiogenic and retinal health-improving effects, showing potential for use in retinal disease research[1][2][3].
  • Product Name Alternative:

    AR-13324 M1 metabolite
  • UNSPSC:

    12352005
  • Hazard Statement:

    H302, H315, H319, H335
  • Target:

    PKC; ROCK
  • Type:

    Reference compound
  • Related Pathways:

    Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; Stem Cell/Wnt; TGF-beta/Smad
  • Field of Research:

    Neurological Disease; Cardiovascular Disease
  • Assay Protocol:

    https://www.medchemexpress.com/ar-13503.html
  • Purity:

    98.21
  • Solubility:

    DMSO : 40 mg/mL (ultrasonic; adjust pH to 3 with HCl)
  • Smiles:

    OCC1=CC=C([C@@H](CN)C(NC2=CC(C=CN=C3)=C3C=C2)=O)C=C1
  • Molecular Formula:

    C19H19N3O2
  • Molecular Weight:

    321.38
  • Precautions:

    H302, H315, H319, H335
  • References & Citations:

    [1]Ding J, et al. ROCK/PKC inhibitor AR-13503 inhibits angiogenesis and protects the barrier function of retinal pigment epithelium[J]. Investigative Ophthalmology & Visual Science, 2018, 59 (9) : 205-205.|[2]Carbajal K, et al. AR-13503 Enhances the efficacy of aflibercept in a mouse model of proliferative diabetic retinopathy[J]. Investigative Ophthalmology & Visual Science, 2018, 59 (9) : 200-200.|[3]Halasz E, et al. AR-13503, a ROCK inhibitor, reduces rod axon retraction during retinal detachment[J]. Investigative Ophthalmology & Visual Science, 2018, 59 (9) : 4221-4221.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    -20°C, 3 years; 4°C, 2 years (Powder)
  • Scientific Category:

    Reference compound1
  • Clinical Information:

    Phase 1
  • CAS Number:

    [2309668-15-1]